US 12,492,263 B2
Anti-HER2 antibodies and immunoconjugates
Xiaocheng Chen, Burlingame, CA (US); Mark Dennis, San Carlos, CA (US); Jagath Reddy Junutula, Fremont, CA (US); Gail Lewis Phillips, San Carlos, CA (US); Thomas Harden Pillow, San Francisco, CA (US); and Mark X. Sliwkowski, San Carlos, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Apr. 14, 2022, as Appl. No. 17/720,717.
Application 16/721,525 is a division of application No. 16/170,819, filed on Oct. 25, 2018, granted, now 10,556,966, issued on Feb. 11, 2020.
Application 16/170,819 is a division of application No. 15/296,454, filed on Oct. 18, 2016, granted, now 10,179,820, issued on Jan. 15, 2019.
Application 15/296,454 is a division of application No. 14/851,001, filed on Sep. 11, 2015, granted, now 9,518,118, issued on Dec. 13, 2016.
Application 17/720,717 is a continuation of application No. 16/721,525, filed on Dec. 19, 2019, abandoned.
Claims priority of provisional application 62/049,594, filed on Sep. 12, 2014.
Prior Publication US 2023/0041134 A1, Feb. 9, 2023
Int. Cl. C07K 16/32 (2006.01); A61K 31/5517 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 31/5517 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 39/3955 (2013.01); A61K 47/68 (2017.08); A61K 47/6809 (2017.08); A61K 47/6849 (2017.08); A61K 47/6855 (2017.08); A61K 47/6863 (2017.08); A61K 49/00 (2013.01); C07K 16/2863 (2013.01); C07K 16/3015 (2013.01); G01N 33/57415 (2013.01); G01N 33/57446 (2013.01); G01N 33/57492 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); G01N 2333/82 (2013.01)] 15 Claims
 
1. An isolated antibody that binds to HER2, wherein the antibody comprises
(i)(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 20 or 21; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;
(ii)(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 22; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;
(iii) a light chain variable region comprising the sequence of SEQ ID NO: 10 and a heavy chain variable region comprising the sequence of SEQ ID NO: 11 with one of the following substitutions: (a) position 53 is serine, position 55 is serine, and position 101 is lysine; (b) position 53 is methionine and position 55 is serine; or (c) position 53 is leucine, wherein positions are numbered according to Kabat numbering; or
(iv) a light chain variable region comprising the sequence of SEQ ID NO: 10 and a heavy chain variable region comprising the sequence of SEQ ID NO: 11 with one of the following substitutions (a) HVR-H2 (SEQ ID NO: 16) is substituted with SEQ ID NO: 8 and HVR-H3 (SEQ ID NO: 17) is substituted with SEQ ID NO: 22; (b) HVR-H2 (SEQ ID NO: 16) is substituted with SEQ ID NO: 20; or (c) HVR-H2 (SEQ ID NO: 16) is substituted with SEQ ID NO: 21.